Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Europe to tackle brain disorder research by linking industry, academia

28.11.2007
Brain disorders including addiction, depression, and schizophrenia afflict 1 billion people and are often incurable with current therapies

Attempts to cure brain-related disorders have proved less successful than therapies for other major conditions such as heart cancer, even though just as many people suffer from them. About 600 million worldwide each year are afflicted by depression alone, more than any other condition except heart disease, and yet of those given existing drugs, only half recover.

Furthermore progress treating depression as well as other major brain disorders has stalled. This stark fact lies behind an ambitious European proposal to revive the field. The proposal, to be presented at EuroBioForum, in Lisbon in December 2007, aims to develop a ground breaking multi-disciplinary research project which would propel Europe to the head of global research into the crucial role of neurotransmitters in brain disorders. Bringing together the relevant specialisms in chemistry, radio-chemistry, in vivo modelling, and above all PET and SPECT scanning, the project would exploit recent advances both in PET (Positron Emission Tomography), and SPECT (Single Photon Emission Computer Tomography), enabling metabolic activity such as levels of neurotransmitters to be determined with greater accuracy in space and quantity.

The objective is to develop new methods to identify the release of neurotransmitters such as noradrenaline, serotonin, acetylcholine, and endorphins, in the brain and so examine their role in major brain disorders. This in turn will enable more effective therapies to be developed than current drugs, which often fail to work, according to the project's leader David Nutt, Professor of Psychopharmacology at the University of Bristol, UK. Professor Nutt is presenting his vision for this groundbreaking project at the EuroBioForum conference, which is organised by the European Science Foundation (ESF) with support from the European Commission.

The programme has great potential for human health given the vast number of people affected, but as Professor Nutt pointed out, the scale of the task is great.

"We don't even know for example whether serotonin levels are high or low in depressed people," said Professor Nutt. This is despite the fact that many current anti-depressant drugs, including Prozac, alter the uptake of serotonin by key receptors in the brain. Professor Nutt's observation shows that there is a lack of knowledge over how existing drugs work, and until greater understanding is reached, it will be very difficult to make further progress.

Until now researchers have been deterred by the sheer extent of the problem in unravelling the complex links between multiple neurotransmitters and a range of conditions. This, said Professor Nutt, is big science on the same level as the Human Genome Project, or splitting the atom. It requires a huge harmonised effort, combining the forces of academia and the pharmaceutical industry. Until now neurological research has tended to be fragmented, with industry more concerned with improving existing therapies and determining correct combinations of drugs and dosage levels. Meanwhile academia has tended to plough too many small furrows, without tackling the big picture.

The EuroBioForum conference will provide the platform for researchers to unite behind a common larger goal. As Professor Nutt commented, "the conference offers a unique opportunity for the academic community, research funding organisations, government, industry and policy making organisations to share ideas and contribute to key policy and funding decisions." He added, "I'm extremely pleased to have been invited to such an important event and delighted that for the first time a brain research programme has been shortlisted under this initiative."

The EuroBioForum conference, held annually and organised by the ESF with support from the EU, is a key event in the European research funding calendar. Its purpose is to provide a platform for representatives from the European scientific community to deliver their vision for grand challenges in the life sciences and so influence future European research funding priorities. The conference offers a unique opportunity for the academic community, research funding agencies, government, industry and policy making organizations, to share ideas and contribute to key funding decisions.

Thomas Lau | alfa
Further information:
http://www.esf.org/activities/eurobiofund/lisbon

Further reports about: Brain EuroBioForum Nutt academia neurotransmitters

More articles from Life Sciences:

nachricht Nesting aids make agricultural fields attractive for bees
20.07.2017 | Julius-Maximilians-Universität Würzburg

nachricht The Kitchen Sponge – Breeding Ground for Germs
20.07.2017 | Hochschule Furtwangen

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Manipulating Electron Spins Without Loss of Information

Physicists have developed a new technique that uses electrical voltages to control the electron spin on a chip. The newly-developed method provides protection from spin decay, meaning that the contained information can be maintained and transmitted over comparatively large distances, as has been demonstrated by a team from the University of Basel’s Department of Physics and the Swiss Nanoscience Institute. The results have been published in Physical Review X.

For several years, researchers have been trying to use the spin of an electron to store and transmit information. The spin of each electron is always coupled...

Im Focus: The proton precisely weighted

What is the mass of a proton? Scientists from Germany and Japan successfully did an important step towards the most exact knowledge of this fundamental constant. By means of precision measurements on a single proton, they could improve the precision by a factor of three and also correct the existing value.

To determine the mass of a single proton still more accurate – a group of physicists led by Klaus Blaum and Sven Sturm of the Max Planck Institute for Nuclear...

Im Focus: On the way to a biological alternative

A bacterial enzyme enables reactions that open up alternatives to key industrial chemical processes

The research team of Prof. Dr. Oliver Einsle at the University of Freiburg's Institute of Biochemistry has long been exploring the functioning of nitrogenase....

Im Focus: The 1 trillion tonne iceberg

Larsen C Ice Shelf rift finally breaks through

A one trillion tonne iceberg - one of the biggest ever recorded -- has calved away from the Larsen C Ice Shelf in Antarctica, after a rift in the ice,...

Im Focus: Laser-cooled ions contribute to better understanding of friction

Physics supports biology: Researchers from PTB have developed a model system to investigate friction phenomena with atomic precision

Friction: what you want from car brakes, otherwise rather a nuisance. In any case, it is useful to know as precisely as possible how friction phenomena arise –...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

»We are bringing Additive Manufacturing to SMEs«

19.07.2017 | Event News

The technology with a feel for feelings

12.07.2017 | Event News

Leipzig HTP-Forum discusses "hydrothermal processes" as a key technology for a biobased economy

12.07.2017 | Event News

 
Latest News

Researchers create new technique for manipulating polarization of terahertz radiation

20.07.2017 | Information Technology

High-tech sensing illuminates concrete stress testing

20.07.2017 | Materials Sciences

First direct observation and measurement of ultra-fast moving vortices in superconductors

20.07.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>